IFNG and myeloid sarcoma: Indeed, the immunomodulators IFN-β and Glatiramer acetate, which constitute the first-line treatment for MS, downregulate the production of chemokines and pro-inflammatory cytokines such as IFN-γ and IL-6 (41, 42).